Pure Global
NCT03965494

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Early Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Brain and Central Nervous System Tumors
Drug/Device/Intervention
BGB 324 (before surgery)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Location
Birmingham,Baltimore,Detroit,New York,Winston-Salem,Philadelphia, United States of America
Timeline & enrollment
Phase
Early Phase 1
Start date
Jan 02, 2020
End date
Dec 01, 2023
Enrollment
20 participants
Primary outcome

Proportion of patients who achieve a drug concentration at = 1.0 uM level in contrast enhancing tumor tissue

Summary

This phase I trial studies how well AXL inhibitor BGB324 works in treating participants with
 glioblastoma that has come back who are undergoing surgery. AXL inhibitor BGB324 may stop the
 growth of tumor cells by blocking some of the enzymes needed for cell growth.

ICD-10 classifications
Malignant neoplasm: Overlapping lesion of brain and other parts of central nervous systemMalignant neoplasm: Central nervous system, unspecifiedBenign neoplasm of brain and other parts of central nervous systemMalignant neoplasm of brainSecondary malignant neoplasm of other and unspecified parts of nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03965494
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03965494 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is currently Recruiting. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.